Overview
HBOT is a UHMS-approved adjunctive therapy for necrotising soft tissue infections (necrotising fasciitis, gas gangrene, Fournier gangrene). Hyperoxia is directly toxic to anaerobic organisms including Clostridium perfringens, and enhances neutrophil-mediated killing of anaerobes. Does not replace surgical debridement.
Necrotising soft tissue infections — including necrotising fasciitis, gas gangrene (clostridial myonecrosis), and Fournier gangrene — are life-threatening emergencies with high mortality. Standard treatment is immediate aggressive surgical debridement, broad-spectrum antibiotics, and critical-care support. HBOT is a validated adjunct that improves outcomes when added to standard care.
The historical case for HBOT is strongest in clostridial gas gangrene, where hyperoxia is directly bactericidal to the anaerobic Clostridium perfringens. Modern necrotising fasciitis is often polymicrobial, but the mechanism extends: enhanced neutrophil function improves killing of a broad range of pathogens.
The clinical evidence base is primarily retrospective case series (randomised trials being ethically difficult in acute life-threatening disease). Wilkinson 2004 and Riseman 1990 are frequently cited for mortality reduction when HBOT is added to standard surgical and antibiotic management.
How HBOT Works for This Condition
Hyperoxia at 2.5–3.0 ATA is directly bactericidal to anaerobes (Clostridium perfringens and others) and bacteriostatic to many facultative organisms. Alpha-toxin production by C. perfringens is suppressed. Neutrophil-mediated bacterial killing — which is oxygen-dependent — is substantially enhanced. Antibiotic penetration into poorly vascularised infected tissue improves.
GRADE Evidence Rating
No RCTs — observational data show mortality benefit. UHMS-approved based on biological plausibility and clinical consensus.
| GRADE Domain | Assessment |
|---|---|
| Risk of bias | Moderate |
| Consistency | Consistent |
| Directness | Direct |
| Precision | Moderate |
GRADE methodology: Grading of Recommendations Assessment, Development and Evaluation. See GRADE Working Group.
Clinical Protocol
| Typical protocol | 3 sessions in first 24 hours at 2.5–3.0 ATA |
|---|---|
| Evidence level | Moderate — UHMS approved |
| FDA status | FDA-approved indication |
Standard protocol: 2.5–3.0 ATA sessions, 90 minutes with air breaks. Three sessions in the first 24 hours (every 6–8 hours), then twice daily for 48 hours, then daily. Coordinated with surgical and critical-care teams. Total 5–20 sessions depending on clinical course.
Evidence Base
UHMS Tier 1. Evidence from retrospective case series; RCTs ethically difficult. Mortality reduction documented in Wilkinson 2004, Riseman 1990, and others.
Cautions & Considerations
- Does not replace urgent surgical debridement — adjunct only.
- Patients are typically critically ill — requires multiplace capability.
- Must be initiated urgently; delay reduces benefit.
Key Research & References
- Wilkinson 2004
- Riseman et al. 1990
- UHMS Indications Manual
Indexed Studies for This Condition
Linked entries in the HBOT Studies Database.
Frequently Asked Questions
Can HBOT alone treat gas gangrene?
No. HBOT is an adjunct to urgent surgical debridement and broad-spectrum antibiotics (penicillin + clindamycin for clostridial infection). All three modalities are standard of care; omitting any reduces survival.
How many sessions are needed?
Typically 5–20 sessions depending on clinical response. Initial intensive phase (3 sessions in 24 hours) followed by de-escalation as the infection resolves.
Research disclaimer: This article summarises published research for educational purposes only. Nothing here is medical advice. HBOT is a prescription medical treatment that must be administered under physician supervision in appropriately certified chambers. Discuss any treatment decisions with a qualified clinician.